Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2005-09-06
2005-09-06
Smith, L. J. (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S150100, C424S164100, C530S387100, C530S388400, C530S387300, C530S388100, C435S007100
Reexamination Certificate
active
06939543
ABSTRACT:
The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.
REFERENCES:
patent: 4027010 (1977-05-01), Kiselev et al.
patent: 4197290 (1980-04-01), Yoshida
patent: 4318902 (1982-03-01), Stephan
patent: 4425330 (1984-01-01), Norcross et al.
patent: 4460575 (1984-07-01), d'Hinterland
patent: 4482483 (1984-11-01), Curry et al.
patent: 4596769 (1986-06-01), Shockman et al.
patent: 4719290 (1988-01-01), Curry et al.
patent: 4732757 (1988-03-01), Stolle et al.
patent: 4744982 (1988-05-01), Hunter et al.
patent: 4761283 (1988-08-01), Anderson
patent: 4789735 (1988-12-01), Frank et al.
patent: 4830852 (1989-05-01), Marburg et al.
patent: 4888279 (1989-12-01), Zeiger
patent: 4902616 (1990-02-01), Fournier et al.
patent: 4954449 (1990-09-01), Hunter et al.
patent: 4965068 (1990-10-01), Stephan et al.
patent: RE33565 (1991-04-01), Stolle et al.
patent: 5034515 (1991-07-01), Proctor
patent: 5043267 (1991-08-01), Richards
patent: 5055455 (1991-10-01), Pier et al.
patent: 5069896 (1991-12-01), Rogers et al.
patent: 5153312 (1992-10-01), Porro
patent: 5175096 (1992-12-01), Höök et al.
patent: 5354654 (1994-10-01), Ligler et al.
patent: 5440014 (1995-08-01), Höök et al.
patent: 5505945 (1996-04-01), Gristina et al.
patent: 5530102 (1996-06-01), Gristina et al.
patent: 5538733 (1996-07-01), Emery et al.
patent: 5545721 (1996-08-01), Caroll et al.
patent: 5571511 (1996-11-01), Fischer
patent: 5585098 (1996-12-01), Coleman
patent: 5624904 (1997-04-01), Krieger et al.
patent: 5652217 (1997-07-01), Höök et al.
patent: 5707627 (1998-01-01), Gristina et al.
patent: 5770208 (1998-06-01), Fattom et al.
patent: 5840846 (1998-11-01), Höök et al.
patent: 5851535 (1998-12-01), Jolivet-Reynaud
patent: 5955074 (1999-09-01), Fischer
patent: 5955078 (1999-09-01), Burnham et al.
patent: 6080407 (2000-06-01), Bucala et al.
patent: 6168790 (2001-01-01), Ulevitch et al.
patent: 6194161 (2001-02-01), Fattom et al.
patent: 6294177 (2001-09-01), Fattom
patent: RE37525 (2002-01-01), Prince et al.
patent: 6355625 (2002-03-01), Pavliak et al.
patent: 6365156 (2002-04-01), Lee
patent: 6372897 (2002-04-01), Colette
patent: 6610293 (2003-08-01), Fischer et al.
patent: 2002/0031528 (2002-03-01), Fattom
patent: 2002/0102262 (2002-08-01), Hook et al.
patent: 2003/0103969 (2003-06-01), Ulevitch et al.
patent: 2003/0119101 (2003-06-01), Burnie et al.
patent: 0 724 016 (1996-07-01), None
patent: 01226828 (1989-09-01), None
patent: WO 89/00999 (1989-02-01), None
patent: WO 90/03398 (1990-04-01), None
patent: WO 93/09811 (1993-05-01), None
patent: 93/09811 (1993-05-01), None
patent: WO 93/17044 (1993-09-01), None
patent: WO 93/19373 (1993-09-01), None
patent: 93/19373 (1993-09-01), None
patent: WO 94/11026 (1994-05-01), None
patent: WO 96/09321 (1996-03-01), None
patent: 96/23896 (1996-08-01), None
patent: WO 96/39518 (1996-12-01), None
patent: WO 97/26010 (1997-07-01), None
Aasjord, P et al, ACTA Pathologica Microbiologica et Immunologica Scandinavica-Section C, Immunology, vol. 93(6), pp. 245-260, 1985 (abstract only).
Fiedel, BA et al, Abstracts of teh Annual Meeting of the American Society for Microbiology, vol. 72, p. 104, 1972 (abstract only).
Stashenko, P et al, Archives of Oral Biology, vol. 31(7), pp. 455-461, 1986 (abstract only).
Wergeland, HI et al, Journal of Clinical Microbiology, vol. 27(6), pp. 1286-1291, 1989, (abstract only).
Gazmuri, et al, The New England Journal of Medicine,Jul. 25, 1991, vol. 325(4), pp. 279-283 “The Ha-1a monoclonal antibody from gram negative sepsis (correspondence)”.
Peake, S, Anaesth. Intens. Care, 1993, vol. 21, pp. 739-751, Monoclonal antibodies-immunotherapy for the critically ill.
Lehner,T. Current Opinion in Immunology, vol. 1(3), pp. 462-466, 1989.
Archibald, Ar et al, Nature-New Biology, Jan. 3, 1973, vol. 241(105), pp. 29-31, Molecular arrangement of teichoic acid in the cell wall ofStaphylococcus lactis.
Brock, JH, Vaccination of the bovine againstStaphylocccal mastitiswith special reference to teichoic acid antibodies and the virulence ofS.aureus, 1972-1973, publ. 1975, Index to Theses, vol. 23, p. 101, Reading University, citation only.
Chugh, TD et al, Infection and Immunity, Feb. 1990, vol. 58(2), pp. 315-319, Feb. 1990, Adherence ofStaphylococcus epidermidisto Fibrin-Platelet clots in vitro mediated by lipoteichoic acid.
Ginsburg, I et al, Inflammation, vol. 12(6), 1988, Lipoteichoic acid-antilipoteichoic acid complexes induce superoxide generation by human neutrophils.
Karakawa, WW et al, Journal of Immunology, vol. 114(1pt2), pp. 310-315, Jan. 1975, Immunochemistry of an acidic antigen isolated from aStaphylocococcus aureus.
Klesius, PH et al, Canadian Journal of microbiology, Jun. 1974, vol. (20)6, pp. 853-859, Human antibody response to a group A streptococcal teichoic acid.
Mancuso, G et al, Infection and Immunity, vol. 62(4), pp. 1470-1473, Apr. 1994, Anti-lipoteichoic acid antibodies enhance release of cytokines by monocytes sensitized with lipoteichoic acid.
Naumova, IB et al, Archives of microbiology, May 1980, vol. 126(1), pp. 71-75, The occurance of teichoic acids in streptomycetes (abstract only).
Ohshima, Y et al, Staphylococcal lipoteichoic acid, a potent simulant of immune cell porliferation, maturation and activation, Zentralblatt Fur Bakteriologie—supplemnet, 1994, issue 26, pp. 437-439.
Prokop, O et al, ACTA biologica et medica Germanica, 1970, vol. 24(3), pp. 19-23 (German article), English title and Descriptors, The therapeutic use of anti-A-HP in the treatment of staphylococcal skin diseases as a result of the affinity of the hetero.
Stashenko, P et al, Archives of oral biology, 1986, vol. 31(7), pp. 455-461, Effect of monoclonal antibodies against lipoteichoic acid from the oral bacteriumStreptococcus mutanson its adhesin and plaque-accumulation in vitro.
Wu, TC et al, Journal of Bacteriology, Nov. 1971, vol. 108(2), pp. 874-884, Chemical characterization of anew surface antigenic polysaccharide from a mutant ofStaphylococcus aureus.
PCT International Search Report, dated Sep. 9, 2003.
Borrebaeck,Antibody Engineering, 2nd Ed., Oxford University Press, NY (1995).
Carruthers and Kabat, Mediation of Staphylococcal Adherence to Mucosal Cells by Lipoteichoic Acid,Infect Immun.40:444-46 (1983).
Current Methods in Hybridoma Formation, Bartal et al. (ed.)Methods of Hybridoma Formation, Humana Press, Clifton, New Jersey (1987).
De Kimpe et al., The Cell Wall Components Peptidoglycan and Lipoteichoic Acid FromS. aureusAct in Synergy to Cause Shock and Multiple Organ Failure,Proc. Nat. Acad. Sci.(USA)92:10359-63 (1995).
Fischer et al., Improved Preparation of Lipoteichoic Acids,Eur. J. Biochem.133:523-30 (1983).
Fournier,Staphylococcus aureus, Vaccines and Immunotherapy, Ch. 13, pp. 166-177 (1991).
Gonzalez and Hill, The Current Status of Intravenous Gamma-globulin Use in Neonates,J. Ped. Infect. Dis.8:315-22 (1989).
Green et al., Antigen-Specific Human Monoclonal Antibodies from Mice Engineered with Human Ig Heavy and Light Chain YACs,Nat. Genet.7:13-21 (1994).
Hancock, Bacterial Cell Surface Carbohydrates: Structure and Assembly,Biochem. Soc. Trans.25:183-87 (1997).
Jendeberg et al., Engineering of Fc1and Fc3From Human Immunoglobulin G to Analyse Subclass Specificity for Staphylococcal Prot
Fischer Gerald W.
Schuman Richard F.
Stinson Jeffrey R.
Wong Hing
Henry M. Jackson Foundation for the Advancement of Military Medi
Porter Ginny Allen
Smith L. J.
Sunol Molecular Corporation
Winston & Strawn LLP
LandOfFree
Opsonic and protective monoclonal and chimeric antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Opsonic and protective monoclonal and chimeric antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Opsonic and protective monoclonal and chimeric antibodies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3382633